Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sub-dissociative Dose Ketamine for Vaso-occlusive Pain in Sickle Cell Disease
NCT07369024Phase 2Recruiting
- Start
- Sep 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ketamine in sickle cell disease (SCD). Started Sep 2026; status: recruiting.
02
Drugs
ketamine
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT07369024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07369024.